<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095481</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-7410-0007</org_study_id>
    <nct_id>NCT04095481</nct_id>
  </id_info>
  <brief_title>Obalon Navigation/Touch System Post-Approval Study</brief_title>
  <acronym>NTS PAS</acronym>
  <official_title>Obalon Navigation/Touch System Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obalon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Obalon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-approval study for the Obalon Navigation/Touch System (NTS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Obalon NTS PAS is a prospective, observational, open-label and multi-center study with an
      objective to collect continued safety and performance of the Obalon NTS in a commercial
      setting and confirm results observed in the supplemental PMA IDE study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Esophageal Inflation</measure>
    <time_frame>Up to 20 Weeks</time_frame>
    <description>Percentage of esophageal Inflation during the balloon administrations using the Obalon NTS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>System Success</measure>
    <time_frame>Up to 20 Weeks</time_frame>
    <description>Percentage of appropriate inflation in the stomach with the use of NTS only (without radiography) or correctly determining failed balloon transit (device in the esophagus) as confirmed by endoscopic removal</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obalon NTS</arm_group_label>
    <description>Patients who commercially purchased the NTS Compatible Obalon Balloon System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Obalon Navigation/Touch System</intervention_name>
    <description>The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon</description>
    <arm_group_label>Obalon NTS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 22 years and older with a starting therapy BMI of 30.0-40.0 kg/m2 and who
        commercially purchased the Obalon Balloon device.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 22 years and older

          2. Starting or current therapy BMI of 30.0-40.0 kg/m2

          3. Commercially purchased the Obalon Balloon Device

        Exclusion Criteria:

          1. Known history of structural or functional disorders of the esophagus that may impede
             passage of the device through the gastrointestinal tract or increase risk of
             esophageal damage during an endoscopic removal procedure, including, Barrett's
             esophagus, esophagitis, dysphagia, achalasia, stricture/stenosis, esophageal varices,
             esophageal diverticula, esophageal perforation or any other disorder of the esophagus.

          2. Known history of structural or functional disorder of the esophagus, including any
             swallowing disorder, esophageal chest pain disorders, or drug refractory esophageal
             reflux symptoms.

          3. Known history of structural or functional disorders of the stomach including,
             gastroparesis, gastric ulcer, chronic gastritis, gastric varices, hiatal hernia (&gt; 2
             cm), cancer or any other disorder of the stomach.

          4. Active implantable devices, such as a pacemaker of defibrillator, or with metal
             implants in the thoracic region.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy VandenBerg</last_name>
    <phone>844.362.2566</phone>
    <email>ClinicalAffairs@obalon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angel Cardeno</last_name>
    <phone>844.362.2566</phone>
    <email>ClinicalAffairs@obalon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ultimate Bariatrics - Flower Mound</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>75028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryanna Henry</last_name>
      <phone>8177834395</phone>
      <email>BHenry@IAmYou.com</email>
    </contact>
    <investigator>
      <last_name>Robert Snow, DO, FACOS, FASMBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ultimate Bariatrics - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryanna Henry</last_name>
      <phone>817-850-1100</phone>
      <email>bhenry@iamyou.com</email>
    </contact>
    <investigator>
      <last_name>Adam B Smith, DO, FACOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

